发布于: Android转发：1回复：6喜欢：3
$Editas Medicine(EDIT)$ 新的华裔首席医学官带来了一些新气象，加码scd/tdt，年底有初步数据发布，已给药scd患者两人，多人已完成采集和编辑。本月还有眼科LCA 10的一个更新。我对这个更新不太看好，但是市场对这个的预期也很低了，万一有好的信号可能也会大涨。可以试试一个投资策略，买点最近的看涨期权，如果数据不行，亏光拉倒，股价下跌以后买股票看涨后面专注于scd/tdt以及卖各种授权。$CRISPR Therapeutics(CRSP)$ $福泰制药(VRTX)$

全部讨论

JZee
2022-11-06 00:06

Let's start with EDIT-301. As Gilmore noted, we recently dosed a second sickle cell disease patient in the Phase I/II RUBY study. Beyond the first 2 patients dosed with EDIT-301, we also have completed apheresis and successfully edited CD4 positive cells from several additional patients...

Edit101 for LCA 10: The update will include available safety data on 12 adults and 2 pediatric patients and efficacy data on adult patients. The adult efficacy update was including 1 year of data from adult mid-dose cohort and 6 months data from the adult high-dose cohort.

箱子里有只羊
2022-11-17 21:00

鉴于人口较少，公司将暂停 BRILLIANCE 试验的招募，并寻求确定合作伙伴以继续开发 EDIT-101

张小丰
2022-11-13 15:27

scd别人都快申报上市了啊